vs
Idexx Laboratories（IDXX）とロバートハーフ（RHI）の財務データ比較。上の社名をクリックして会社を切り替えられます
ロバートハーフの直近四半期売上が大きい（$1.3B vs $1.1B、Idexx Laboratoriesの約1.2倍）。Idexx Laboratoriesの前年同期比売上増加率が高い（14.3% vs -5.8%）。Idexx Laboratoriesの直近四半期フリーキャッシュフローが多い（$326.3M vs $170.8M）。過去8四半期でIdexx Laboratoriesの売上複合成長率が高い（6.4% vs -6.1%）
IDEXXラボラトリーズは1983年設立の米国多国籍企業で、伴侶動物獣医療、家畜・家禽、水質検査、乳製品分野向けの製品・サービスの開発・製造・流通を手がけています。本社はメイン州ウェストブルックにあり、EMEA地域の拠点はオランダのホーフドルプに置かれています。
ロバートハーフは1948年に設立された国際的な人材コンサルティング企業で、カリフォルニア州メンロパークとサンラモンに本社を置いています。世界最大級の会計・財務分野の人材派遣会社の1つで、全世界に345を超える拠点を展開しています。
IDXX vs RHI — 直接比較
売上が大きい
RHI
1.2倍大きい
$1.1B
売上成長率が高い
IDXX
+20.1%の差
-5.8%
フリーキャッシュフローが多い
IDXX
FCF $155.5M多い
$170.8M
2年売上CAGRが高い
IDXX
2年複合成長率
-6.1%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.1B | $1.3B |
| 純利益 | $248.2M | — |
| 粗利率 | 60.3% | 37.6% |
| 営業利益率 | 28.9% | 1.7% |
| 純利益率 | 22.8% | — |
| 売上前年比 | 14.3% | -5.8% |
| 純利益前年比 | 14.8% | — |
| EPS（希薄化後） | $3.09 | $0.32 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上IDXXRHI
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $998.4M | $1.4B | ||
| Q4 24 | $954.3M | $1.4B | ||
| Q3 24 | $975.5M | $1.5B | ||
| Q2 24 | $1.0B | $1.5B | ||
| Q1 24 | $964.1M | $1.5B |
純利益IDXXRHI
| Q4 25 | $248.2M | — | ||
| Q3 25 | $274.6M | $42.9M | ||
| Q2 25 | $294.0M | $41.0M | ||
| Q1 25 | $242.7M | $17.4M | ||
| Q4 24 | $216.1M | — | ||
| Q3 24 | $232.8M | $65.5M | ||
| Q2 24 | $203.3M | $68.2M | ||
| Q1 24 | $235.6M | $63.7M |
粗利率IDXXRHI
| Q4 25 | 60.3% | 37.6% | ||
| Q3 25 | 61.8% | 37.2% | ||
| Q2 25 | 62.6% | 37.2% | ||
| Q1 25 | 62.4% | 36.9% | ||
| Q4 24 | 59.8% | 38.8% | ||
| Q3 24 | 61.1% | 39.0% | ||
| Q2 24 | 61.7% | 39.2% | ||
| Q1 24 | 61.5% | 38.1% |
営業利益率IDXXRHI
| Q4 25 | 28.9% | 1.7% | ||
| Q3 25 | 32.1% | 1.0% | ||
| Q2 25 | 33.6% | 0.1% | ||
| Q1 25 | 31.7% | 2.9% | ||
| Q4 24 | 27.4% | 4.7% | ||
| Q3 24 | 31.2% | 4.1% | ||
| Q2 24 | 26.3% | 5.1% | ||
| Q1 24 | 31.0% | 2.8% |
純利益率IDXXRHI
| Q4 25 | 22.8% | — | ||
| Q3 25 | 24.8% | 3.2% | ||
| Q2 25 | 26.5% | 3.0% | ||
| Q1 25 | 24.3% | 1.3% | ||
| Q4 24 | 22.7% | — | ||
| Q3 24 | 23.9% | 4.5% | ||
| Q2 24 | 20.3% | 4.6% | ||
| Q1 24 | 24.4% | 4.3% |
EPS（希薄化後）IDXXRHI
| Q4 25 | $3.09 | $0.32 | ||
| Q3 25 | $3.40 | $0.43 | ||
| Q2 25 | $3.63 | $0.41 | ||
| Q1 25 | $2.96 | $0.17 | ||
| Q4 24 | $2.62 | $0.53 | ||
| Q3 24 | $2.80 | $0.64 | ||
| Q2 24 | $2.44 | $0.66 | ||
| Q1 24 | $2.81 | $0.61 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.1M | $464.4M |
| 総負債低いほど良い | $450.0M | — |
| 株主資本純資産 | $1.6B | $1.3B |
| 総資産 | $3.4B | $2.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.28× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資IDXXRHI
| Q4 25 | $180.1M | $464.4M | ||
| Q3 25 | $208.2M | $365.3M | ||
| Q2 25 | $164.6M | $380.5M | ||
| Q1 25 | $164.0M | $342.5M | ||
| Q4 24 | $288.3M | $537.6M | ||
| Q3 24 | $308.6M | $570.5M | ||
| Q2 24 | $401.6M | $547.4M | ||
| Q1 24 | $397.4M | $540.9M |
総負債IDXXRHI
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
株主資本IDXXRHI
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.6B | $1.5B | ||
| Q1 24 | $1.6B | $1.5B |
総資産IDXXRHI
| Q4 25 | $3.4B | $2.9B | ||
| Q3 25 | $3.4B | $2.8B | ||
| Q2 25 | $3.3B | $2.8B | ||
| Q1 25 | $3.2B | $2.7B | ||
| Q4 24 | $3.3B | $2.9B | ||
| Q3 24 | $3.4B | $3.0B | ||
| Q2 24 | $3.4B | $2.9B | ||
| Q1 24 | $3.4B | $2.9B |
負債/資本比率IDXXRHI
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $355.8M | $182.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $326.3M | $170.8M |
| FCFマージンFCF / 売上 | 29.9% | 13.1% |
| 設備投資強度設備投資 / 売上 | 2.7% | 0.9% |
| キャッシュ転換率営業CF / 純利益 | 1.43× | — |
| 直近12ヶ月FCF直近4四半期 | $1.1B | $266.8M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローIDXXRHI
| Q4 25 | $355.8M | $182.5M | ||
| Q3 25 | $402.3M | $77.4M | ||
| Q2 25 | $185.7M | $119.4M | ||
| Q1 25 | $238.0M | $-59.3M | ||
| Q4 24 | $262.0M | $154.8M | ||
| Q3 24 | $220.1M | $129.6M | ||
| Q2 24 | $248.3M | $142.0M | ||
| Q1 24 | $198.6M | $-15.9M |
フリーキャッシュフローIDXXRHI
| Q4 25 | $326.3M | $170.8M | ||
| Q3 25 | $371.2M | $63.6M | ||
| Q2 25 | $151.6M | $104.2M | ||
| Q1 25 | $207.9M | $-71.7M | ||
| Q4 24 | $232.8M | $140.5M | ||
| Q3 24 | $192.0M | $111.8M | ||
| Q2 24 | $215.0M | $129.6M | ||
| Q1 24 | $168.3M | $-27.7M |
FCFマージンIDXXRHI
| Q4 25 | 29.9% | 13.1% | ||
| Q3 25 | 33.6% | 4.7% | ||
| Q2 25 | 13.7% | 7.6% | ||
| Q1 25 | 20.8% | -5.3% | ||
| Q4 24 | 24.4% | 10.2% | ||
| Q3 24 | 19.7% | 7.6% | ||
| Q2 24 | 21.4% | 8.8% | ||
| Q1 24 | 17.5% | -1.9% |
設備投資強度IDXXRHI
| Q4 25 | 2.7% | 0.9% | ||
| Q3 25 | 2.8% | 1.0% | ||
| Q2 25 | 3.1% | 1.1% | ||
| Q1 25 | 3.0% | 0.9% | ||
| Q4 24 | 3.1% | 1.0% | ||
| Q3 24 | 2.9% | 1.2% | ||
| Q2 24 | 3.3% | 0.8% | ||
| Q1 24 | 3.1% | 0.8% |
キャッシュ転換率IDXXRHI
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.47× | 1.80× | ||
| Q2 25 | 0.63× | 2.91× | ||
| Q1 25 | 0.98× | -3.42× | ||
| Q4 24 | 1.21× | — | ||
| Q3 24 | 0.95× | 1.98× | ||
| Q2 24 | 1.22× | 2.08× | ||
| Q1 24 | 0.84× | -0.25× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
